All In Biotech

Drug Trial Radar · NCT04777201

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,036

Actual

Start

Apr 19, 2021

Primary completion

Sep 3, 2024

Study completion Sep 3, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval (PTI) to participants with neovascular age-related macular degeneration (nAMD) who enrolled in and completed one of the Phase III studies: GR40306 (NCT03823287) or GR40844 (NCT03823300), also referred to as the parent studies. Eligible patients who consent to participate in this main study will be enrolled upon completion of the end-of-study visit in the parent study. Additionally, there is a substudy that is being conducted. The aim of this substudy is to evaluate the impact of intravitreal faricimab on the health of the corneal endothelial cells in the study eyes of patients with nAMD to fulfill a U.S. Food and Drug Administration (FDA) post-marketing requirement. The fellow eyes of the same enrolled participants in the substudy will serve as the controls.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

  • FaricimabDrug

    Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.

  • Sham ProcedureOther

    The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 12 weeks of this study in order to maintain the masking of the initial faricimab PTI.

  • Anti-VEGF TherapyDrug

    At the discretion of the principal investigator, participants were allowed to have their fellow (non-study) eye treated with the standard of care anti-VEGF therapy (if needed) according to region-specific anti-VEGF prescribing information for the recommended dose and frequency of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading ScaleTime frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
  2. Incidence of Ocular Adverse Events in the Fellow EyeTime frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
  3. Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading ScaleTime frame: From the date of first administration of faricimab through 28 days after the end of study (up to 2 years)
  4. Substudy: Percent Change in Corneal Endothelial Cell Density From Baseline at 1 Year in the Study Eye as Compared With the Fellow EyeTime frame: Baseline and 1 year

Locations

251 sites in 27 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center

    Mesa, Arizona

  • Arizona Retina and Vitreous Consultants

    Phoenix, Arizona

  • Associated Retina Consultants

    Phoenix, Arizona

  • Retina Associates Southwest PC

    Tucson, Arizona

  • Retinal Diagnostic Center

    Campbell, California

  • The Retina Partners

    Encino, California

  • South Coast Retina Center

    Los Angeles, California

  • Northern California Retina Vitreous Associates

    Mountain View, California

  • Southern CA Desert Retina Cons

    Palm Desert, California

  • California Eye Specialists Medical group Inc.

    Pasadena, California

  • Retina Consultants, San Diego

    Poway, California

  • Retina Consultants of Southern California

    Redlands, California

  • University of California, Davis, Eye Center

    Sacramento, California

  • Retinal Consultants Med Group

    Sacramento, California

  • Orange County Retina Med Group

    Santa Ana, California

  • California Retina Consultants

    Santa Barbara, California

  • Retina Consultants of Southern

    Colorado Springs, Colorado

  • Colorado Retina Associates, PC

    Lakewood, Colorado

  • Retina Group of New England

    Waterford, Connecticut

  • Rand Eye

    Deerfield Beach, Florida

  • Retina Group of Florida

    Fort Lauderdale, Florida

  • Florida Eye Associates

    Melbourne, Florida

  • Retina Care Specialists

    Palm Beach Gardens, Florida

  • Retina Specialty Institute

    Pensacola, Florida

  • Fort Lauderdale Eye Institute

    Plantation, Florida

  • Retina Vitreous Assoc of FL

    St. Petersburg, Florida

  • Southern Vitreoretinal Assoc

    Tallahassee, Florida

  • Retina Associates of Florida, LLC

    Tampa, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Georgia Retina PC

    Marietta, Georgia

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii

  • Northwestern Medical Group/Northwestern University

    Chicago, Illinois

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Prairie Retina Center

    Springfield, Illinois

  • Raj K. Maturi, MD PC

    Indianapolis, Indiana

  • Wolfe Eye Clinic

    West Des Moines, Iowa

  • Retina Associates

    Lenexa, Kansas

  • Maine Eye Center

    Portland, Maine

  • Retina Specialists

    Baltimore, Maryland

  • The Retina Care Center

    Baltimore, Maryland

Showing 40 of 251 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.